Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M411766200 on January 24, 2005

J. Biol. Chem., Vol. 280, Issue 13, 13019-13028, April 1, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/13/13019    most recent
M411766200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rahmani, M.
Right arrow Articles by McManus, B. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rahmani, M.
Right arrow Articles by McManus, B. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Regulation of the Versican Promoter by the {beta}-Catenin-T-cell Factor Complex in Vascular Smooth Muscle Cells*

Maziar Rahmani{ddagger}, Jason T. Read§, Jon M. Carthy{ddagger}, Paul C. McDonald{ddagger}, Brian W. Wong{ddagger}, Mitra Esfandiarei{ddagger}, Xiaoning Si{ddagger}, Zongshu Luo{ddagger}, Honglin Luo{ddagger}, Paul S. Rennie§, and Bruce M. McManus{ddagger}

From the {ddagger}James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, St. Paul's Hospital, 1081 Burrard Street, Vancouver, British Columbia V6Z 1Y6, Canada and §Prostate Center, Vancouver General Hospital, Vancouver, British Columbia V6T 2B5, Canada

Received for publication, October 15, 2004 , and in revised form, January 20, 2005.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The proteoglycan versican is pro-atherogenic and central to vascular injury and repair events. We identified the signaling pathways and promoter elements involved in regulation of versican expression in vascular smooth muscle cells. Phosphatidylinositol 3-kinase inhibitor, LY294002, significantly decreased versican-luciferase (Luc) promoter activity and endogenous mRNA levels. We further examined the roles of protein kinase B and glycogen synthase kinase (GSK)-3{beta}, downstream effectors of phosphatidylinositol 3-kinase, in the regulation of versican transcription. Co-transfection of dominant negative and constitutively active protein kinase B constructs with a versican-Luc construct decreased and increased promoter activity, respectively. Inhibition of GSK-3{beta} activity by LiCl augmented accumulation of {beta}-catenin and caused induction of versican-Luc activity as well as versican mRNA levels. {beta}-Catenin has no DNA binding domain, therefore it cannot directly induce transcription of the versican promoter. Software analysis of the versican promoter revealed two potential binding sites for T-cell factors (TCFs), proteins that confer transcriptional activation of {beta}-catenin. Electrophoretic mobility shift and supershift assays revealed specific binding of human TCF-4 and {beta}-catenin to oligonucleotides corresponding to a potential TCF binding site in the versican promoter. In addition to binding assays, we directly assessed the dependence of versican promoter activity on TCF binding sites. Site-directed mutagenesis of the TCF site located -492 bp relative to the transcription start site markedly diminished versican-Luc activity. Co-transfection of TCF-4 with versican-Luc did not increase promoter activity, but addition of {beta}-catenin and TCF-4 significantly stimulated basal versican promoter activity. Our findings suggest that versican transcription is predominantly mediated by the GSK-3{beta} pathway via the {beta}-catenin-TCF transcription factor complex in smooth muscle cells, wherein such regulation contributes to the normal or aberrant formation of provisional matrix in vascular injury and repair events.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Findings from our laboratory and others indicate that the proteoglycan (PG)1 versican is one of several extracellular matrix (ECM) molecules that accumulates in vascular lesions (1–3). Versican is generally considered to be pro-atherogenic because of its ability to trap cholesterol-rich lipoproteins (4–6) in addition to its crucial role in regulation of cell adhesion, survival, proliferation, and migration and ECM assembly, all fundamental processes involved in vascular disease (4–7).

The complete versican gene structure has been elucidated in humans (8, 9) and the mouse (10). The human and murine genes prove to be remarkably conserved in genomic organization. Both versican genes extend for ~90 kb and contain 15 exons that align in an identical manner with the protein sub-domains. Naso et al. (9) report that the human versican gene has one transcription start site. Meanwhile, sequence analysis reveals potential binding sites for several transcription factors in addition to the TATA box. Transient expression assays of reporter constructs driven by an 876-bp (-632/+240 relative to the transcriptional start site) piece of the versican promoter in HeLa cells and IMR-90 embryonic lung fibroblasts have shown significant expression. These results indicate that the human versican 5'-flanking sequence contains promoter and enhancer elements able to drive reporter gene expression in cells derived from epithelial or mesenchymal tissues (9).

Various growth factors and mediators influence the expression of versican. Studies using arterial smooth muscle cells (SMCs) have demonstrated that transforming growth factor {beta}1 and platelet-derived growth factor (PDGF)-AB increase versican mRNA levels, core protein synthesis, and glycosaminoglycan chain length (11). Similarly, normal human gingival fibroblasts respond to treatment with either transforming growth factor {beta} or PDGF-BB by increasing versican mRNA levels (12, 13). In contrast, the pro-inflammatory cytokine interleukin-1{beta} appears to decrease the synthesis of this PG in human gingival fibroblasts and arterial SMCs (14). Data from recent investigations suggest that versican synthesis by mesanchymal cells can be regulated by physical stimuli, including cell density and mechanical strain (15). In vitro experiments using monkey arterial SMCs have shown that PDGF-BB stimulates versican core protein expression; this signaling apparently occurs through a receptor tyrosine kinase-dependent, protein kinase C-independent pathway (16). Angiotensin II-mediated stimulation of SMC versican expression is regulated by epidermal growth factor receptor-dependent tyrosine kinase pathways (17).

The canonical Wnt-wingless signaling pathway regulates various biologic processes including early embryogenesis and neoplasia by increasing the stability and transcriptional activity of a key mediator, {beta}-catenin (18–20). In the absence of Wnt ligand, GSK-3 promotes the phosphorylation of {beta}-catenin at key serine/threonine residues, targeting it for degradation through the ubiquitin-ligase pathway (21). In response to Wnt, the GSK-3-binding protein inhibits GSK-3 activity (22). Some growth factors can regulate GSK-3 activity by mediating its phosphorylation at serine 9 independent of Wnt ligand. Although serine 9 phosphorylation of GSK-3 is associated with its inactivation, Wnt ligand does not necessarily regulate this phosphorylation (23). GSK-3 inactivation leads to {beta}-catenin stabilization and translocation into the nucleus, where it binds to T-cell factor(TCF)/lymphoid enhancer factor (LEF) family proteins to form a transcription factor complex that activates target genes such as the matrix metalloproteinase-7, fibronectin, vascular endothelial growth factor, cyclin D1, and c-myc (24).

A variety of mitogenic stimuli including Wnts, insulin, epidermal growth factor, and PDGF result in catalytic inactivation of GSK-3. The catalytic inactivation of GSK-3 induced by most polypeptide mitogens is reversible by treatment with serine/threonine-specific phosphates (25). The inactivation event has been demonstrated to be due to phosphorylation of serine 21 and serine 9 of GSK-3{alpha} and GSK-3{beta}, respectively (26–28). These residues are specific targets for several protein-serine kinases, including PKB, pp90rsk, and cyclic AMP-dependent protein kinase A (29, 30). The inactivating biochemical consequence of phosphorylation by all three enzymes is identical; what differs is the initiating signal. Thus, activation of the phosphatidylinositol 3-kinase (PI3K) pathway (usually via receptor tyrosine kinase activation) results in stimulation of PKB. Inactivation of GSK-3 in response to many mitogens can be inhibited by antagonists of PI3K such as LY294002 inhibitor (25). These mechanisms are all independent of Wnt-induced regulation of GSK-3. Most protein kinases are induced by cellular stimuli, whereas GSK-3 is shut down. In addition, the enzyme has a broad variety of target proteins, most of which are inactivated by phosphorylation of GSK-3. Thus, inhibition of this one enzyme will tend to induce the functions of a diverse array of targets including transcription factors and other regulatory molecules (31).

Despite the importance of versican in vascular pathophysiology, the function and regulation of expression of this versatile molecule in vitro and in vivo are unknown. Our results suggest that a signaling molecule activated by 3-phosphoinositides, namely PKB, plays a critical role in serum-stimulated versican transcription. Furthermore, we provide evidence that phosphorylation and inhibition of GSK-3{beta} by PKB and subsequent activation of the {beta}-catenin-TCF complex are essential for transcription from the versican promoter.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Isolation and Primary Culture of Rat Aortic SMCs—A rat aortic SMC culture was established by a modification of the enzymatic dispersion technique (32, 33). Briefly, four adult male Fisher rats (275–350 g) were euthanized in accordance with ethical guidelines set by the University of British Columbia Animal Care Committee. The thoracic aorta was removed and immediately washed in MCDB-131 medium (Sigma-Aldrich). Enzyme I (0.5 mg/ml collagenase II; Worthington Biochemical Corp., Freehold, NJ) was applied to the exposed media, and the tissue was incubated for 20 min at 37 °C to loosen the media from the underlying adventitia. Medial strips were removed with sterile forceps, taking care not to reach the adventitial layer, transferred to a 35-mm tissue culture dish containing 500 µl of Enzyme II (0.5 mg/ml collagenase II, 0.2 mg/ml elastase; Worthington Biochemical Corp.), and minced. Medial tissue from the aortas of all four rats was pooled, additional Enzyme II solution was added to the dish, and the tissue was incubated at 37 °C for 2.5 h with pipetting at regular intervals to disperse cells. Liberated cells were subsequently pelleted at 1000 rpm for 5 min, resuspended in 1 ml of MCDB-131 containing 20% newborn calf serum, and seeded into a 35-mm tissue culture dish. Cells were grown to confluence, released by trypsinization, and subcultured at a density of 1.0 x 104 cells/cm2 in MCDB-131 supplemented with 5% newborn calf serum.

Cell Culture—Rat vascular SMCs were maintained in MCDB-131 plus 5% newborn calf serum as described previously in a controlled atmosphere of air-CO2 (5%) at 37 °C until confluence (6–7 days). Confluent SMCs at passages 4–8 were used for experiments. Human prostate cancer PC3 cells were maintained in Dulbecco's modified Eagle's medium (Sigma) supplemented with 5% fetal bovine serum (Invitrogen) at 37 °C in 5% CO2. A stable HeLa cell line expressing dominant negative mutant of PKB1 construct (DN-PKB), constitutively activated mutant of PKB1 (CA-PKB), and corresponding empty plasmids was generated and selected as described previously (34).

Generation of Promoter Reporter, Mutant, and Deletion Constructs—A 752-bp versican promoter (-634/+118) and a shorter fragment (-438/+118) corresponding to the versican promoter sequences (9) were generated by PCR from human genomic DNA with the appropriate sets of primers (available upon request). These inserts were cloned into a pGL3 basic vector (Promega) by standard molecular biology techniques and called wt-versican-Luc and -438del-versican-Luc as depicted in Fig. 5A. The putative TCF binding sites (TCCCTTTGATGG and TTCTTTGCTGAT at positions -546 and -492 bp, respectively) contained in the wt-versican-Luc were mutated as denoted in Fig. 5A by site-directed mutagenesis using a QuikChange mutagenesis kit from Stratagene as described previously (35). The mutated inserts were generated by PCR and then inserted into the promoterless luciferase vector pGL3-Basic. All constructs were verified by sequencing.



View larger version (27K):
[in this window]
[in a new window]
  		FIG. 5.
The TCF/LEF binding sequence at position -492 is crucial for activation of the versican promoter by the {beta}-catenin-TCF complex. A, schematic representation of the sequence for TCF/LEF binding sites in wild-type human versican promoter and mutant constructs. Two putative TCF/LEF binding sites are localized at position -546 and -492 bp from the transcription start site. Mutations known to abolish TCF binding were introduced into the TCF/LEF recognition sites to make the mutant constructs -546mut-versican-Luc, -492mut-versican-Luc, and -546/-492mut-versican-Luc in the context of the wt-versican-Luc promoter. A deletion construct lacking the TCF/LEF binding sites, -438del-versican-Luc, was also generated as described under "Experimental Procedures." B, mutation at position -492 of the versican promoter inhibits versican luciferase promoter activity. SMCs were transfected with wt-versican-Luc or mutant versican promoter luciferase vectors and harvested 24 h post-transfection. The values are representative of three independent experiments, each performed in duplicate, and are shown relative to the activity of luciferase at cells transfected with wt-versican-Luc construct. C, mutation at position -492 of the versican promoter inhibited the response of luciferase promoter activity to LiCl treatment and {beta}-catenin transactivation in SMCs. SMCs containing normal endogenous {beta}-catenin were transiently transfected with 0.5 µg of wt-versican-Luc and treated with 30 mM LiCl. The cells were co-transfected with 0.8 µg of {beta}-catenin expression vector or an equal amount of empty vector and harvested 24 h after transfection. Total amounts of plasmid DNA were kept constant by adding the empty pCDNA3.1 vector. All experiments were performed in duplicate and repeated at least three times. Values represent mean ± S.D. D, a deletion construct lacking the TCF/LEF binding sequences showed no {beta}-catenin-mediated versican promoter transacativation. SMCs were transfected with wt-versican-Luc or -438del-versican-Luc reporter, along with {beta}-catenin (0.8 µg) or empty vector, as indicated in the figure. Total amounts of plasmid DNA were kept constant by adding the empty pCDNA3.1 vector. All experiments were performed in duplicate and repeated at least three times. Values represent mean ± S.D.

 
Plasmid Constructs—The DN-PKB (Upstate Biotechnology), CA-PKB (Upstate Biotechnology), and empty vector control were used in transient and stable transfection of SMCs and HeLa cells, respectively. The cDNAs for wild-type PTEN (wt-PTEN) and its mutant (mut-PTEN) were kindly provided by J. Dixon (Department of Pharmacology, University of California, San Diego, CA) and subcloned into pXJ41-neo expression vector kindly provided by C. Pallen (Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada). A dominant stable {beta}-catenin construct was a kind gift of B. Gumbiner (Cellular Biochemistry and Biophysics Program, Memorial Sloan-Kettering Cancer Center, New York, NY). The expression vectors TCF-1E and TCF-4E harboring the wild-type human TCF-4 gene and chimeric TCF-1 construct lacking C-terminal binding protein (CtBP) structural domain, respectively, were a gift from A. Hecht (Max-Planck-Institute of Immunobiology, Freiburg, Germany) (36). The myc-tagged dominant negative TCF-4 ({Delta}NTCF-4) was kindly provided by H. Clevers (Department of Immunology, University Medical Center Utrecht, The Netherlands) (37). Wild-type GSK-3{beta} was a kind gift from G. Cooper (Department of Pathology, Harvard Medical School, Boston, MA) (38).

Transfection and Luciferase Activity Assays—Starved SMCs were transiently transfected in 6-well plates using up to 2 µg of plasmid DNA and FuGENE 6 reagent (Roche Applied Science) according to the procedure recommended by the manufacturer. In brief, a 3:1 ratio of FuGENE 6 reagent (in microliters) to plasmid (in micrograms) was incubated for 30 min at room temperature in incomplete medium before addition to 70–80% subconfluent cells in medium containing the mediator of interest or in complete medium for the period of time indicated in the figure legends. After the indicated incubation period, cells were lysed, and luciferase activities were measured with a kit from Promega according to the manufacturer's protocol. Protein concentrations were measured with a Bradford protein assay kit from Bio-Rad, and luciferase values were normalized to the obtained protein concentrations. In some transfection experiments, normalization was done by LacZ reporter (Promega), and {beta}-galactosidase assays were performed according to the manufacturer's protocol.

Immunoblotting—SMCs were grown in 6-well plates. Cells were lysed with 200 µl of lysis buffer. For PKB, lysis buffer contained 50 mM HEPES (pH 7.6), 1 mM EDTA, 5 mM EGTA, 10 mM MgCl2, 50 mM {beta}-glycerophosphate, 1 mM Na3VO4, 10 mM NaF, 30 mM sodium pyrophosphate, 2 mM dithiothreitol, and 1 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride. For GSK-3, lysis buffer contained 20 mM Tris (pH 7.5), 25 mM {beta}-glycerophosphate, 100 mM NaCl, 1 mM Na3VO4, 2 mM EGTA, 2 µg/ml leupeptin, 1 µg/ml aprotinin, and 1 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride. Samples were subjected to SDS-PAGE and transferred onto nitrocellulose membranes. The membranes were probed with anti-phospho-PKB (Ser-473; Cell Signaling Technology) or anti-phospho-GSK-3 (Ser-9; Oncogene Research Product) antibodies. Horseradish peroxidase-conjugated goat anti-rabbit or anti-mouse antibodies were used as secondary antibodies. The levels of wt-PTEN and mut-PTEN were determined 48 h post-transfection of PC3 cells by Western blot analysis using antibody against PTEN (Santa Cruz Biotechnology). The bound secondary antibody was detected by enhanced chemiluminescence (Amersham Biosciences).

RNA Extraction and cDNA Synthesis—Total RNA was isolated from treated and untreated SMCs using the RNeasy Mini Kit according to the manufacturer's protocol (Qiagen). All preparations were treated with RNase-free DNase (Qiagen) to remove genomic DNA. RNA (0.5–1 µg) was reverse transcribed in a total volume of 20 µl in the presence of 200 units of SuperScript RNase H-Reverse Transcriptase (Invitrogen), 40 units of RNaseOUT Recombinant Ribonuclease Inhibitor (Invitrogen), and 0.5 µg of Oligo(dT) Primer (Invitrogen) according to the manufacturer's instructions.

SYBR Green Quantitative Real-time Reverse Transcription-PCR— Quantitative two-step real-time reverse transcription-PCR was performed using a LightCycler (Roche Applied Science) in order to assess versican mRNA expression in SMCs. {beta}-Actin was used as a housekeeping gene. Primer pairs were designed to flank an intron-containing sequence. PCR conditions used included 3 mM Mg2+, 0.3 µM forward and reverse primers, and 2 µl of LightCycler FastStart DNA Master SYBR Green I Mix (Roche Applied Science) in a final volume of 20 µl. The samples were loaded in the LightCycler glass capillaries, closed, centrifuged, and placed in the LightCycler rotor. The cycling program consisted of 10 min of initial denaturation at 95 °C, 45 cycles of 95 °C for 5 s, 55 °C for 5 s, and 72 °C for 20 s, and single detection for 1 s with a single fluorescence acquisition (ramp rates, 20 °C/s). The analytical melting program was 95 °C for 0 s and 65 °C for 15 s, increasing to 95 °C at a ramp rate of 0.2 °C/s, with continuous fluorescence acquisition. Each sample was run in triplicate. A standard curve was included in each run. Standards were prepared by cloning the target sequence into plasmid DNA. The data were analyzed by using the second-derivative maximum of each amplification reaction and relating it to its respective standard curve. The results from the quantitative PCR were expressed as the ratio of the mean target gene measurements to the mean housekeeping gene value for a given sample (target:reference).

Electrophoretic Mobility Shift Assay—Individual oligonucleotides were 5'-end [{gamma}-32P]deoxyadenine triphosphate-labeled with T4 polynucleotide kinase. Labeled oligonucleotides (100 ng) were annealed to equimolar amounts of their complementary strands (unlabeled) by heating to 95 °C for 5 min in Tris-EDTA supplemented with 50 mM NaCl and slowly cooling to room temperature. Double-stranded oligonucleotide probes were purified on a 5% (w/v) polyacrylamide, 0.5x Tris-borate EDTA non-denaturing gel; eluted in 500 µl of elution buffer (0.6 M NH4OAC, 0.1% (w/v) SDS, and 1 mM EDTA); and ethanol precipitated prior to use in electrophoretic mobility shift assays (EMSAs). Nuclear extracts used in EMSAs were isolated from SW480 human colorectal carcinoma cells, using a modified version of the method of Dignam et al. (39). Final nuclear protein preparations were collected in buffer C (400 mM NaCl, 20 mM HEPES (pH 7.4), 25% glycerol, 1.5 mM MgCl2, 0.2 mM EDTA, and 0.5 mM dithiothreitol). For band shift experiments, 20,000 cpm of labeled oligoduplex probes were added to 5 µl of nuclear extracts in 40 µl of DNA binding buffer (10% glycerol, 1 mM EDTA, 1 mM dithiothreitol, and 60 mM KCl). To prevent nonspecific binding of nuclear proteins, poly(dI-dC) was added to a concentration of 100 ng/µl, and the binding reaction was incubated at room temperature for 10 min prior to electrophoresis. For supershift experiments, 1 µg of goat anti-TCF-4 polyclonal antibody (N-20; 0.4 µg/µl; Santa Cruz Biotechnology) was added to the binding reaction and incubated for 10 min at room temperature prior to electrophoresis. For EMSA interference experiments, 0.2 and 0.4 µg of goat anti-{beta}-catenin polyclonal antibody was used (H-102; 0.4 µg/µl; Santa Cruz Biotechnology). For both supershift and interference experiments, antibody control reactions contained an equivalent mass of normal mouse IgG, and antibody negative reactions were supplemented with an equal volume of phosphate-buffered saline. Protein-DNA complexes were separated from unbound DNA using a 5% (w/v) polyacrylamide, 0.5x Tris-borate EDTA non-denaturing gel run at a constant voltage of 400 V for 1 h. The oligonucleotides corresponding to the TCF/LEF site from versican promoter used for EMSAs were as follows: 5'-ACTTCCCTTTGATGGGACAG-3' and 5'-CTGTCCCATCAAAGGGAAGT-3'.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
The 3-Phosphoinositide-dependent Signaling Mediates Versican Transcription in Vascular SMCs—We examined the role of the PI3K-PKB pathway in induction of versican transcription as a result of serum stimulation in vascular SMCs. First, the levels of activated PKB were determined by Western blot analysis using phosphospecific antibody, after a 30-min pre-incubation of quiescent SMCs with different concentrations of LY294002, a pharmacological inhibitor of PI3K, followed by serum stimulation. LY294002 inhibited activation of downstream PKB at all concentrations tested (Fig. 1A). Next we examined whether activation of PI3K and subsequent generation of 3-phosphoinositides is necessary for the stimulation of versican transcription by serum. We transfected SMCs with wild-type versican-Luc reporter construct, and 24 h after transfection, serum-starved, growth-arrested cells were pretreated with LY294002 for 30 min prior to stimulation with 5% newborn calf serum for 24 h. Versican promoter activation was significantly inhibited (Fig. 1B). We next determined the role of the PI3K pathway in the induction of expression of versican mRNA by real-time reverse transcription-PCR analysis. SMCs were growth-arrested for 24 h, pretreated with LY294002 for 30 min, and stimulated with 5% serum for 24 h. The induction of versican mRNA expression by serum was significantly suppressed by LY294002 pretreatment (Fig. 1C). These results suggest that reduced production of 3-phosphoinositides inhibits versican transcription (Fig. 1, A and B). To examine further the role of 3-phosphoinositides, we investigated the role of PTEN (phosphatase and tensin homolog deleted on chromosome 10) in control of versican expression. PTEN is a phosphatase that selectively dephosphorylates the 3 position of both phosphatidylinositol-3,4,5-trisphosphate and phosphatidylinositol-3,4-bisphosphate (40), antagonizing the diverse downstream signaling effector pathways activated by PI3K-derived phospholipids. To investigate the effects of this protein on versican expression levels, we overexpressed it in a cell line normally lacking PTEN, the PC3 prostate cancer cell line. In Fig. 2A, the first lane shows the levels of endogenous PTEN in HeLa cells. The other three lanes show PTEN expression in PC3 cells transiently transfected with empty vector, wt-PTEN expression vector, and mut-PTEN expression vector expressing a lack of functional PTEN. The results of the co-transfection of the versican-Luc plasmid with empty vector, wt-PTEN, and mut-PTEN are shown in Fig. 2B. Expression of wt-PTEN and mut-PTEN reduces and increases promoter function, respectively, which supports our previous findings regarding the role of PI3K in versican promoter regulation. Taken together, these results are consistent with the notion that increases in 3-phosphoinositide levels are necessary for serum-induced increases in versican transcription.



View larger version (33K):
[in this window]
[in a new window]
  		FIG. 1.
PI3K is involved in versican promoter activity and transcription in SMCs. A, inhibition of the PI3K signaling pathway inhibited PKB phosphorylation in SMCs. Confluent serum-starved (24 h) SMCs were pretreated with Me2SO or various concentrations of LY294002 for 30 min and then stimulated with 10% newborn calf serum for 30 min. The levels of activated PKB were determined by Western blot analysis using phosphospecific antibody (anti-phospho-S473 PKB) (top panel). Blots were stripped and reprobed with anti-PKB antibody (bottom panel) to normalize for PKB protein. B, inhibition of PI3K signaling reduces versican promoter reporter activity in SMCs. SMCs (50–70% confluent) were transfected with versican-luciferase reporter (2 µg). After 3 h, the DNA-liposome mixture was removed, and cells were kept in MCDB-131 medium containing 0.2% bovine serum albumin. Twenty-four hours post-transfection, the cells were pretreated with Me2SO or LY294002 (10, 20, and 40 µM) for 30 min and then stimulated with 10% newborn calf serum for 24 h. Cell extracts were obtained, and luciferase activity was assayed. Transfection efficiency was monitored by co-transfecting the cells with 0.2 µg of Rous sarcoma virus/{beta}-galactosidase construct. The values are representative of three independent experiments, each performed in duplicate or triplicate, and are shown relative to the luciferase activity of cells treated with Me2SO (which was set to equal 1). Values are mean ± S.D. C, inhibition of PI3K in SMCs reduces versican mRNA levels. Confluent serum-starved (24 h) SMCs were pretreated with Me2SO or LY294002 (10, 20, and 40 µM) for 30 min and then stimulated with 10% newborn calf serum for 24 h. Total RNA was isolated, and the versican mRNA level was quantified by real-time reverse transcription-PCR as described under "Experimental Procedures." Expression was normalized with respect to {beta}-actin RNA levels in the same samples and presented relative to mRNA level from the cells treated with Me2SO. Results shown are the mean ± S.D. of two cDNA samples analyzed in duplicates representative of three independent experiments. Asterisk denotes a significant difference (p < 0.05) between versican expression in cells treated with LY294002 and Me2SO.

 



View larger version (34K):
[in this window]
[in a new window]
  		FIG. 2.
PTEN inhibits versican promoter activity in PC3 cells. A, transient overexpression of wt-PTEN, mut-PTEN, and corresponding empty plasmids in PC3 cells. PC3 cells were transiently co-transfected with the wt-versican-Luc plasmid and either empty vector or constructs expressing wt-PTEN or mut-PTEN as described under "Experimental Procedures." The levels of wt-PTEN and mut-PTEN were determined 48 h post-transfection by Western blot analysis using an antibody against PTEN. B, overexpression of wild-type PTEN blocks serum-mediated induction of versican promoter reporter in PC3 cells. Transient transfection of PC3 cells with the wt-versican promoter plasmid together with either empty vector or a construct expressing wt-PTEN or mut-PTEN. Data are expressed as fold induction with the induction of luciferase activity from versican-Luc relative to empty vector. Induction of reporter activity in the presence of wt-PTEN differed significantly from empty plasmid controls. Co-transfection of wt-versican-Luc plasmid with mut-PTEN lacking lipid phosphatases activity did not show significant reporter augmentation in response to serum.

 
PKB Is a Downstream Effector of PI3K in Serum Stimulation of Versican Transcription in SMCs—PKB was suggested to be a major downstream mediator of the PI3K in gene regulation in SMCs (41). To investigate whether it is also involved in the serum stimulation of versican transcription, we co-transfected expression vectors for either a DN-PKB plasmid that is incapable of being phosphorylated in response to different stimuli or a CA-PKB expression plasmid with versican-Luc into SMCs. Empty vector was used as a control plasmid. As shown in Fig. 3, A and B, DN-PKB expression significantly decreased versican promoter activity, and CA-PKB significantly increased versican promoter activity, as compared with the corresponding empty vector control. To further study the contribution of PKB to versican regulation, we used HeLa cells stably transfected with DN-PKB, CA-PKB, or empty vector control plasmids. As expected, the DN-PKB mutant blocked PKB1 phosphorylation and activation in transfected HeLa cells when compared with control cells as determined by measuring the phosphorylation of PKB1 and GSK-3{alpha}/{beta}, a PKB-regulated downstream protein (Fig. 3F). In contrast, HeLa cells stably transfected by CA-PKB significantly augmented phosphorylation of PKB1 and GSK-3{alpha}/{beta} as compared with control cells containing empty vector (Fig. 3E). We transiently transfected a versican-Luc reporter construct into HeLa cells stably expressing CA-PKB, DN-PKB, and corresponding empty vectors (Fig. 3, C-E). The results were similar to those observed in transient transfections; versican promoter activity was significantly increased and decreased in HeLa cells stably transfected with CA-PKB and DN-PKB, respectively. The effects of DN-PKB and CA-PKB expression on versican-Luc activity are similar to those seen when PI3K is inhibited by LY294002 treatment or on co-transfection of the mut-PTEN expression construct. Overall, these data suggest that PKB is a downstream mediator of PI3K in the serum regulation of versican transcription in SMCs.



View larger version (39K):
[in this window]
[in a new window]
  		FIG. 3.
Overexpression of DN-PKB and CA-PKB blocks and augments induction of versican promoter reporter, respectively. A, transient overexpression of CA-PKB increases versican promoter reporter activity. SMCs were transiently co-transfected with the wt-versican-Luc plasmid and either empty vector or CA-PKB construct in serum-free conditions as described under "Experimental Procedures." Data are expressed as fold induction relative to empty vector control transfections. B, transient overexpression of DN-PKB decreases versican promoter reporter activity. SMCs were transiently co-transfected with the wt-versican-Luc plasmid and either empty vector or DN-PKB construct in the presence of 10% newborn calf serum as described under "Experimental Procedures." Data are expressed as fold induction relative to empty vector controls. C, stable overexpression of CA-PKB in HeLa cells increases versican promoter reporter activity. Transient transfection of wt-versican-Luc into HeLa cells constitutively expressing CA-PKB or corresponding empty vector in serum-free condition. Twenty-four hours post-transfection, cells were harvested, and luciferase reporter activity was measured as described under "Experimental Procedures." Data are expressed as fold induction compared with cells stably transfected with empty vector. D, stable overexpression of DN-PKB in HeLa cells decreases versican promoter reporter activity. Transient transfection of wt-versican-Luc promoter into HeLa cells constitutively expressing DN-PKB or corresponding empty vector in the presence 10% newborn calf serum. Twenty-four hours post-transfection, cells were harvested, and luciferase reporter activity was measured as described under "Experimental Procedures." Data are expressed as fold induction compared with cells stably transfected with empty vector. E and F, stable overexpression of CA-PKB and DN-PKB in HeLa cells results in a sustained increase and decrease (respectively) in GSK-3{beta}/{alpha} phosphorylation (inactive form). Confluent HeLa cells constitutively expressing CA-PKB, DN-PKB, or corresponding empty vector were harvested, and cell lysate was prepared for assessment of levels of phosphorylated PKB and GSK-3{beta}/{alpha}. The levels of activated PKB were determined by Western blot analysis using the phosphospecific antibody, anti-phospho-Ser-473 PKB (top panels). The levels of a phosphorylated GSK-3{beta} were analyzed by immunoblotting with anti-phospho (Ser-9 and Ser-21)-GSK-3{beta}/{alpha} antibodies (bottom panels).

 
Cytoplasmic Accumulation of {beta}-Catenin via GSK-3{beta} Inhibition Stimulates Transcription of Versican in SMCs—We have used various approaches to show the role of GSK-3{beta} in versican regulation (Fig. 4A). To assess whether GSK-3{beta} is involved in up-regulation of versican expression via {beta}-catenin, SMCs were transfected with the versican-Luc promoter construct and treated with 30 mM LiCl, an inhibitor of GSK-3{beta}. LiCl is an inhibitor of GSK-3 that induces accumulation of dephosphorylated {beta}-catenin and increases the activity of synthetic TCF-dependent reporter constructs. Addition of LiCl resulted in a more than 2-fold increase in versican promoter activity (Fig. 4A). Up-regulation of versican mRNA was also evidenced in SMCs after treatment with 30 mM LiCl (Fig. 4B). To confirm the involvement of GSK-3{beta} in versican activation, SMCs were co-transfected with increasing amounts of GSK-3{beta} expression vector, and this was shown to dose-dependently decrease versican promoter activity (Fig. 4C). These findings are consistent with our results using another inhibitor of GSK-3B, SB415286, which caused a similar increase in versican-Luc promoter activity and versican mRNA levels (data not shown). Our results support the notion that GSK-3{beta} regulates versican transcription in SMCs via accumulation of {beta}-catenin.



View larger version (26K):
[in this window]
[in a new window]
  		FIG. 4.
GSK-3{beta} inhibition stimulates transcription of versican in SMCs. A, lithium chloride, a GSK-3{beta} inhibitor, increased versican promoter luciferase activity. SMCs were transfected with wt-versican-Luc reporter (2 µg/well). After 3 h, the DNA-liposome mixture was removed, and cells were kept in serum-free medium containing 0.2% bovine serum albumin for 24 h. Twenty-four hours post-transfection, the cells were incubated in the presence or absence of LiCl (30 mM) for 24 h. Cell extracts were obtained, and luciferase activity was assayed. Transfection efficiency was monitored by co-transfecting the cells with 0.2 µg/well Rous sarcoma virus/{beta}-galactosidase construct as described under "Experimental Procedures." The values are representative of three independent experiments, each performed in duplicate or triplicate, and are shown relative to the activity of luciferase of cells treated with vehicle. Values are mean ± S.D. B, lithium chloride increased versican mRNA levels. Confluent serum-starved (24 h) SMCs were incubated in the presence or absence of LiCl (30 mM) for 24 h. Total RNA was isolated, and the versican mRNA level was quantified by real-time reverse transcription-PCR as described under "Experimental Procedures." Expression was normalized with respect to {beta}-actin RNA level in the same samples and presented relative to mRNA level from untreated cells. Results shown are the mean ± S.D. of two cDNA samples analyzed in duplicates representative of two independent experiments. Asterisk denotes a significant difference (p < 0.05) between versican expression in cells treated with LiCl and those treated with vehicle. C, GSK-3{beta} inhibited versican promoter activity. SMCs were co-transfected with the versican-Luc reporter and wild-type GSK-3{beta} construct or with the empty vector, incubated for 24 h in the presence of 5% serum, and assayed for luciferase activity. The values are representative of three independent experiments, each performed in duplicate or triplicate, and are shown relative to the luciferase activity in cells transfected with empty plasmid. Values are mean ± S.D.

 
TCF/LEF DNA Binding Is Involved in {beta}-Catenin-induced Versican Transcription—{beta}-Catenin contains no DNA binding domain and therefore cannot regulate versican promoter activity directly. The proximal versican promoter was searched for transcription factor binding sites that would confer {beta}-catenin transactivation. A search for consensus TCF binding sites in the versican promoter using the MatInspector program (42) revealed the presence of two potential TCF/LEF binding sites, TCCCTTTGATGG and TTCTTTGCTGAT sequences, at positions -546 bp and -492 bp, respectively (Fig. 5A). To determine the functional significance of consensus TCF/LEF binding sequences at nucleotides -546 to -534 and -492 to -480, we first employed 5' promoter deletion construct (Fig. 5A). We co-transfected SMCs with a versican-Luc deletion construct lacking the TCF/LEF binding sites (-438del-versican-Luc) and {beta}-catenin expression plasmids. Of the deletion reporter showed no {beta}-catenin-induced versican promoter activation (Fig. 5B), the functional significance of the consensus TCF/LEF binding motifs was assessed further by introducing point mutations in the sites within the versican-Luc promoter (Fig. 5A). In SMCs, basal activity of the -546mut-versican-Luc construct was not significantly different from that of wt-versican-Luc, but -492mut-versican-Luc and -546/-492mut-versican-Luc showed significantly lower basal versican promoter activity (9-fold), indicating that the TCF binding site at position -492mut-versican-Luc plays a critical role in versican promoter function and potentially contributes to a significant extent to constitutive versican expression in these cells (Fig. 5C). We observed similar effects of these mutations on versican promoter activity in the SW480 colon carcinoma cell line and HeLa cells (data not shown). Moreover, the mutation of the TCF/LEF binding motif abolished transactivation of this construct by {beta}-catenin in SMCs (Fig. 5D) as well as in other cell types (data not shown). These results indicate that induction of versican by {beta}-catenin is controlled at the transcriptional level and depends on a TCF/LEF binding site.

The Versican Promoter Is Activated by the {beta}-Catenin-TCF Complex—The presence of possible TCF/LEF binding motifs in the versican promoter prompted us to examine the effects of {beta}-catenin and TCF-4 expression on versican promoter activity. Co-transfection of versican-Luc with a {beta}-catenin expression vector significantly and dose-dependently increased versican promoter activity (Fig. 6A). These results demonstrate that the accumulation of cytosolic {beta}-catenin results in increased versican promoter activity.



View larger version (31K):
[in this window]
[in a new window]
  		FIG. 6.
The versican promoter is activated by {beta}-catenin-TCF complex. A, {beta}-catenin induces wt-versican-Luc promoter activity in SMCs. SMCs containing normal endogenous {beta}-catenin were transiently co-transfected with 0.5 µg of wt-versican-Luc, along with 0.8 and 1.6 µg of {beta}-catenin expression vector or an equal amount of empty vector, and harvested 24 h after transfection. Total amounts of plasmid DNA were kept constant by adding the corresponding empty vector. All experiments were performed in duplicate and repeated at least three times. Values represent mean ± S.D. B, TCF-4E inhibits versican promoter activation in the absence of {beta}-catenin but induces activation in the presence of {beta}-catenin. SMCs were co-transfected with the versican-Luc promoter construct and the TCF-4 isoform expression vector, TCF-4E, which contains the CtBP structural domain in the absence and presence of {beta}-catenin co-transfection. Cell lysates were harvested and analyzed for luciferase activity after 36 h. C, TCF-1E induces a significant increase in promoter activity in the absence and presence of {beta}-catenin. SMCs were co-transfected with a versican-Luc promoter construct and a chimeric TCF-1 expression vector, TCF-1E, that lacks CtBP structural domain in the absence and presence of {beta}-catenin co-transfection. Cell lysates were harvested and analyzed for luciferase activity after 36 h. D, {Delta}NTCF-4 expression vector decreases {beta}-catenin-induced versican promoter activity in SMCs. SMCs were transiently transfected with 0.5 µg of wt-versican-Luc, 0.5 µgof {beta}-catenin expression vector, and 0.5 µgof {Delta}NTCF-4 expression vector or corresponding empty vector. Total amounts of plasmid DNA were kept constant by adding the empty pCDNA3.1 vector. All experiments were performed in duplicate and repeated at least three times. Values represent mean ± S.D.

 
In humans, there are four known isoforms of TCF, LEF-1, TCF-1, TCF-3, and TCF-4; the most conserved portions among these transcription factors are the {beta}-catenin binding domain and the high mobility group box, the latter of which facilitates DNA binding. Some isoforms of TCF do not possess the {beta}-catenin binding domain or contain domains that function as repressors such as CtBP binding structural domains and can therefore act in a dominant negative fashion. These isoforms are incapable of activating transcription and thought to ordinarily function as tumor suppressors. These differences are thought to contribute to the bimodal behavior of TCFs, through which they are known to be capable of both repression and activation. We co-transfected the versican-Luc reporter vector with the TCF-4 expression vector containing the CtBP binding domain in the absence or presence of a {beta}-catenin expression plasmid. The results showed that TCF-4 inhibited versican promoter activity in the absence of {beta}-catenin but was able to induce versican promoter activation in the presence of {beta}-catenin (Fig. 6B). In contrast, co-transfection of the versican-Luc reporter with a TCF-1 chimeric construct (TCF-1E) that does not contain a CtBP domain does not inhibit promoter activity, and versican promoter activity significantly increased, regardless of the co-transfection of {beta}-catenin (Fig. 6C). These findings support a repressor role for CtBP in {beta}-catenin-mediated versican promoter activation by TCFs. To assess whether versican transcriptional activation was TCF-4-dependent, we performed a co-transfection of the {beta}-catenin expression vector with a dominant negative mutant ({Delta}NTCF-4) devoid of {beta}-catenin binding domains. The {Delta}NTCF-4 mutant inhibited {beta}-catenin-driven transactivation (Fig. 6D).

Taken together, these data suggest that the {beta}-catenin-TCF complex activates the versican promoter in SMCs. Our data also suggest the levels of different isoforms of TCF transcription factors containing different repressor or co-activator domains may determine the repression of TCF target genes, including versican, in SMCs.

TCF-4 Binds to the Versican TCF/LEF Site—In the next set of experiments, we analyzed the binding of nuclear extract protein to the TCF/LEF site in the versican promoter by gel shift analysis (Fig. 7). Oligonucleotides corresponding to the indicated DNA elements were labeled with 32P and incubated with nuclear extract derived from the SW480 human colorectal cancer cell line. The versican TCF site element showed a strong double shift consistent with previously observed TCF4 and TCF4-{beta}-catenin complexes and a supershift on addition of anti-TCF4 antibodies (43, 44) (Fig. 7A). Addition of anti-{beta}-catenin antibodies to the shift experiment resulted in interference of the formation of the larger complex, which is consistent with antibody binding preventing the TCF4/{beta}-catenin interaction (Fig. 7B).



View larger version (69K):
[in this window]
[in a new window]
  		FIG. 7.
EMSA of a potential TCF-4 binding site in the versican promoter. A double-stranded oligonucleotide corresponding to a potential TCF-4 binding site within the versican promoter was radiolabeled and incubated with nuclear extracts derived from the SW480 cell line. The indicated antibodies were added to the DNA binding reaction prior to electrophoresis. Anti-TCF-4 antibodies generated a supershifted complex (A), whereas anti-{beta}-catenin antibodies interfered with the formation of the higher molecular weight complex present in the control reactions (B).

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
In the present study, we found that PI3K and its downstream effector PKB mediate serum stimulation of versican transcription in SMCs. Furthermore, we showed that cytoplasmic accumulation of {beta}-catenin via inhibition of GSK-3{beta} stimulates transcription of versican. Finally, we demonstrated that a TCF/LEF binding site in the versican promoter is involved in {beta}-catenin-induced versican transcription and that at least one of the members of TCF family of transcription factors, TCF-4, binds to the TCF/LEF site in the human versican promoter. These observations may support a new concept for the pathophysiological role of PI3K/PKB/GSK-3{beta} signaling through the {beta}-catenin-TCF transactivation complex, modulating the gene expression patterns observed in atheromatous lesions and provisional matrix formation involved in normal and aberrant vascular injury and repair processes (1–7, 45).

Numerous studies have demonstrated that after mechanical arterial injury, vessel walls follow a response to injury pattern of wound healing leading to restenosis secondary to the neointimal accumulation of SMCs and ECM, with the ECM accounting for >90% of the neointimal volume (46, 47). The PG versican is one of several ECM molecules that accumulate in vascular lesions (1, 2). Versican is generally considered to be pro-atherogenic because of its ability to trap cholesterol-rich lipoproteins (4, 6) in addition to its role in regulation of fundamental events involved in vascular disease (4, 6, 7). The dynamic process of vascular injury and repair involves molecular signaling cascades that govern arterial SMC migration, differentiation, proliferation, and fate (48–50). The canonical Wnt-wingless signaling pathway regulates various biologic processes including early embryogenesis, neoplasia, and healing by increasing the stability and transcriptional activity of a key mediator, {beta}-catenin (51–53). Upon its stabilization and accumulation (51–53), {beta}-catenin translocates to the nucleus and activates the TCF/LEF family of transcription factors (53). Evidence suggests a potentially important role for the {beta}-catenin/TCF signaling in vascular remodeling events (54–57). The present study suggests that upon activation of growth factor receptors and Wnt signaling, {beta}-catenin increases and activates TCF target genes, including versican, which, in turn, retains atherogenic lipoproteins and contributes to lesion development. The production of versican also influences cellular functions and survival directly or indirectly. Our finding may suggest one of the molecular mechanisms by which versican influences vascular injury and repair events.

In vitro experiments using monkey arterial SMCs show that PDGF-stimulated versican core protein expression apparently occurs through a receptor tyrosine kinase-dependent, protein kinase C-independent pathway (16). The concentration- and time-dependent increase in mRNA levels by AT1 receptor-expressing cells in response to angiotensin II is inhibited by the AT1 receptor antagonist losartan, the epidermal growth factor receptor inhibitor AG1478, and the mitogen-activated protein kinase inhibitor PD98059. The increase in versican gene expression was not inhibited by the protein kinase C inhibitors chelerythrine and staurosporine, indicating that angiotensin II-mediated stimulation of SMC versican expression is regulated by receptor tyrosine kinase-dependent mechanisms (17). Our data, for the first time, suggest that PI3K/PKB signaling is involved in the serum regulation of versican transcription in SMCs. We established this regulatory sequence of events in a series of experiments. First, we showed that the pharmacological inhibitor of PI3K, LY294002, inhibited activation of downstream PKB at all concentrations tested and resulted in significant inhibition of versican promoter reporter activity and a reduced versican mRNA level in SMCs. Furthermore, consistent with previous results, expression of wt-PTEN and mut-PTEN reduced and increased versican promoter function, respectively. PTEN antagonizes the diverse downstream signaling effector pathways activated by PI3K-derived phospholipids, which supports our previous finding regarding the role of PI3K in versican promoter regulation. PKB was suggested to be a major downstream effector of PI3K-related gene regulation in SMCs. Finally, the results of our experiments demonstrate that versican promoter activity of versican-Luc was significantly increased and decreased in transient co-transfection with CA-PKB and DN-PKB constructs, respectively. Overall, these results suggest that reduced production of 3-phosphoinositides inhibits serum-induced PKB signaling stimulation of versican transcription in SMCs.

GSK-3 inactivation leads to {beta}-catenin stabilization and translocation into the nucleus, where {beta}-catenin binds to TCF/LEF family proteins to form a transcription factor complex that activates target genes such as matrix metalloproteinase-7, fibronectin, vascular endothelial growth factor, cyclin D1, and c-myc (24). Recent work suggests a role for the Wnt/{beta}-catenin signaling pathway in pathophysiological remodeling within the cardiovascular system (21, 22, 59, 60). There is also evidence that differential inhibition of GSK-3{beta} in intimal tissue following vascular injury acts as a critical signal mediating SMC survival (21). Finally, Mao et al. (56) recently demonstrated altered expression of the Frizzled receptor family in SMCs in response to vascular injury.

There is a recent report that the versican gene was identified as a target gene of Wnt signaling using microarray technology to analyze human embryonic carcinoma cells stimulated with active Wnt protein (61). The promoters of nearly all the target genes identified include putative TCF binding sites including the versican promoter. Kishimoto et al. (58) also showed that co-culture of cells expressing a secreted Wnt3a protein maintains the expression of green fluorescent protein placed under the control of a fragment of the human versican promoter. In this study, we have observed that versican gene expression is up-regulated by {beta}-catenin. We show that endogenous versican mRNA is induced in SMCs by LiCl treatment, which inactivates GSK-3 and therefore stabilizes wild-type {beta}-catenin. This regulation occurs at the transcriptional level because the versican promoter responded to {beta}-catenin in the presence or absence of co-transfected TCF-4 expression plasmid, whereas dominant negative TCF-4 expression inhibited these effects. Our data demonstrate that a single consensus TCF/LEF binding sequence located -492 bp from the transcriptional start site is critical for {beta}-catenin responsiveness, thus identifying versican as a direct target of the {beta}-catenin-TCF complex. We also show a potential repressor function of some TCF isoforms on versican transcriptional activity by co-transfecting a versican promoter reporter and a vector expressing a TCF-4 isoform containing a CtBP structural domain in the presence or absence of {beta}-catenin expression plasmid. The results showed the CtBP domain of TCF-4 mediated inhibition of versican promoter activation in the absence of {beta}-catenin but was able to induce versican promoter activity in the presence of {beta}-catenin. In contrast, co-transfection of the versican promoter with a TCF chimeric construct that does not contain CtBP domains did not repress promoter activity (data not shown). These findings support the hypothesis that certain TCF isoforms containing the CtBP structural domain can repress TCF target genes such as versican. Taken together, these data suggest that {beta}-catenin-TCF complex activates the versican promoter in SMCs. Our data also suggest that the level of different isoforms of TCF transcription factors containing different repressor or co-activator domains determines the repression activity of TCF on target genes in SMCs.

In conclusion, we suggest that the PI3K/PKB pathway plays a critical role in serum-stimulated versican transcription. Furthermore, we provide evidence that phosphorylation and inhibition of GSK-3{beta} by PKB and subsequent {beta}-catenin-TCF complex formation are essential for versican transcription (Fig. 8). The roles of versican in cell growth, motility, adhesion, and angiogenesis strongly indicate that this PG of the ECM is an important downstream effector of the Wnt pathway during developmental and pathological processes. We also suggest that {beta}-catenin, through regulation of this versatile PG versican and other candidate target genes, augments the establishment of a provisional ECM, induces proliferation and survival of vascular cells, and modulates adhesive, migratory, and angiogenic processes that lead to normal or aberrant vascular injury and repair.



View larger version (24K):
[in this window]
[in a new window]
  		FIG. 8.
Hypothetical model of versican promoter regulation via PI3K/PKB signaling and {beta}-catenin-TCF transcription factor complex. In the resting cells, under unstimulated conditions, cytoplasmic {beta}-catenin is associated with GSK-3{beta} and other scaffolding proteins, and GSK-3{beta} is active and phosphorylates {beta}-catenin in the cytoplasm and renders it susceptible to degradation via the ubiquitin-proteosome pathway. Activation of PI3K or Wnt signaling leads to phosphorylation of GSK-3{beta} but induces inactivation of GSK and destabilizes the destruction complex, and {beta}-catenin accumulates in the cytoplasm and subsequently translocates to the nucleus. Nuclear accumulation of {beta}-catenin leads to complexing with TCF/LEF transcription factors and transactivation of TCF/LEF target genes. Our findings support the model that versican transcription is predominantly mediated by activation of PI3K/PKB and subsequent phosphorylation/inhibition of the GSK-3{beta} pathway via {beta}-catenin-TCF transcription factor complex at the versican promoter in vascular SMCs.

 

   FOOTNOTES
 
* This work was supported by a grant-in-aid from the Heart and Stroke Foundation of British Columbia and Yukon (to B. M. M.), doctoral research awards from the Heart and Stroke Foundation of Canada (to M. R.), a graduate fellowship of University of British Columbia (to M. R.), and a doctoral award from the Ministry of Health and Medical Education of Iran. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

To whom correspondence should be addressed. Tel.: 604-806-8586; Fax: 604-806-9274; E-mail: bmcmanus{at}mrl.ubc.ca.

1 The abbreviations used are: PG, proteoglycan; ECM, extracellular matrix; GSK, glycogen synthase kinase; Luc, luciferase; MCDB, molecular and cellular developmental biology-131; PI3K, phosphatidylinositol 3-kinase; PKB, protein kinase B; SMC, smooth muscle cell; TCF, T-cell factor; LEF, lymphoid enhancer factor; PDGF, platelet-derived growth factor; DN-PKB, dominant negative mutant of PKB1 construct; CA-PKB, constitutively activated mutant of PKB1; CtBP, C-terminal binding protein; wt-PTEN, wild-type PTEN; mut-PTEN, mutant PTEN; EMSA, electrophoretic mobility shift assay. Back



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Farb, A., Kolodgie, F. D., Hwang, J. Y., Burke, A. P., Tefera, K., Weber, D. K., Wight, T. N., and Virmani, R. (2004) Circulation 110, 940-947[Abstract/Free Full Text]
  2. Lin, H., Wilson, J. E., Roberts, C. R., Horley, K. J., Winters, G. L., Costanzo, M. R., and McManus, B. M. (1996) J. Heart Lung Transplant. 15, 1233-1247[Medline] [Order article via Infotrieve]
  3. Lin, H., Kanda, T., Hoshino, Y., Takase, S., Kobayashi, I., Nagai, R., and McManus, B. M. (1998) Cardiovasc. Pathol. 7, 31-37[Medline] [Order article via Infotrieve]
  4. Williams, K. J., and Tabas, I. (1995) Arterioscler. Thromb. Vasc. Biol. 15, 551-561[Free Full Text]
  5. Williams, K. J. (2001) Curr. Opin. Lipidol. 12, 477-487[CrossRef][Medline] [Order article via Infotrieve]
  6. Rahmani, M., McDonald, P. C., Wong, B. W., and McManus, B. M. (2004) Can. J. Cardiol. 20, 58B-65B.[Medline] [Order article via Infotrieve]
  7. Wight, T. N., and Merrilees, M. J. (2004) Circ. Res. 94, 1158-1167[Abstract/Free Full Text]
  8. Iozzo, R. V., Naso, M. F., Cannizzaro, L. A., Wasmuth, J. J., and McPherson, J. D. (1992) Genomics 14, 845-851[CrossRef][Medline] [Order article via Infotrieve]
  9. Naso, M. F., Zimmermann, D. R., and Iozzo, R. V. (1994) J. Biol. Chem. 269, 32999-33008[Abstract/Free Full Text]
  10. Naso, M. F., Morgan, J. L., Buchberg, A. M., Siracusa, L. D., and Iozzo, R. V. (1995) Genomics 29, 297-300[CrossRef][Medline] [Order article via Infotrieve]
  11. Schonherr, E., Jarvelainen, H. T., Sandell, L. J., and Wight, T. N. (1991) J. Biol. Chem. 266, 17640-17647[Abstract/Free Full Text]
  12. Kahari, V. M., Larjava, H., and Uitto, J. (1991) J. Biol. Chem. 266, 10608-10615[Abstract/Free Full Text]
  13. Haase, H. R., Clarkson, R. W., Waters, M. J., and Bartold, P. M. (1998) J. Cell. Physiol. 174, 353-361[CrossRef][Medline] [Order article via Infotrieve]
  14. Qwarnstrom, E. E., Jarvelainen, H. T., Kinsella, M. G., Ostberg, C. O., Sandell, L. J., Page, R. C., and Wight, T. N. (1993) Biochem. J. 294, 613-620[Medline] [Order article via Infotrieve]
  15. Lee, R. T., Yamamoto, C., Feng, Y., Potter-Perigo, S., Briggs, W. H., Landschulz, K. T., Turi, T. G., Thompson, J. F., Libby, P., and Wight, T. N. (2001) J. Biol. Chem. 276, 13847-13851[Abstract/Free Full Text]
  16. Schonherr, E., Kinsella, M. G., and Wight, T. N. (1997) Arch. Biochem. Biophys. 339, 353-361[CrossRef][Medline] [Order article via Infotrieve]
  17. Shimizu-Hirota, R., Sasamura, H., Mifune, M., Nakaya, H., Kuroda, M., Hayashi, M., and Saruta, T. (2001) J. Am. Soc. Nephrol. 12, 2609-2615[Abstract/Free Full Text]
  18. Polakis, P. (2000) Genes Dev. 14, 1837-1851[Free Full Text]
  19. Taipale, J., and Beachy, P. A. (2001) Nature 411, 349-354[CrossRef][Medline] [Order article via Infotrieve]
  20. Korswagen, H. C., and Clevers, H. C. (1999) Cold Spring Harbor Symp. Quant. Biol. 64, 141-147[CrossRef][Medline] [Order article via Infotrieve]
  21. Aberle, H., Bauer, A., Stappert, J., Kispert, A., and Kemler, R. (1997) EMBO J. 16, 3797-3804[CrossRef][Medline] [Order article via Infotrieve]
  22. Ding, V. W., Chen, R. H., and McCormick, F. (2000) J. Biol. Chem. 275, 32475-32481[Abstract/Free Full Text]
  23. Doble, B. W., and Woodgett, J. R. (2003) J. Cell Sci. 116, 1175-1186[Abstract/Free Full Text]
  24. Goodwin, A. M., and D'Amore, P. A. (2002) Angiogenesis 5, 1-9[Medline] [Order article via Infotrieve]
  25. Cross, D. A., Alessi, D. R., Vandenheede, J. R., McDowell, H. E., Hundal, H. S., and Cohen, P. (1994) Biochem. J. 303, 21-26[Medline] [Order article via Infotrieve]
  26. Sutherland, C., Leighton, I. A., and Cohen, P. (1993) Biochem. J. 296, 15-19[Medline] [Order article via Infotrieve]
  27. Stambolic, V., and Woodgett, J. R. (1994) Biochem. J. 303, 701-704[Medline] [Order article via Infotrieve]
  28. Shaw, M., Cohen, P., and Alessi, D. R. (1997) FEBS Lett. 416, 307-311[CrossRef][Medline] [Order article via Infotrieve]
  29. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. (1995) Nature 378, 785-789[CrossRef][Medline] [Order article via Infotrieve]
  30. Fang, X., Yu, S. X., Lu, Y., Bast, R. C., Jr., Woodgett, J. R., and Mills, G. B. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 11960-11965[Abstract/Free Full Text]
  31. Hardt, S. E., and Sadoshima, J. (2002) Circ. Res. 90, 1055-1063[Abstract/Free Full Text]
  32. Thyberg, J. (1996) Int. Rev. Cytol. 169, 183-265[Medline] [Order article via Infotrieve]
  33. Campbell, J. H., and Campbell, G. R. (1993) Clin. Sci. (Lond.) 85, 501-513[Medline] [Order article via Infotrieve]
  34. Esfandiarei, M., Luo, H., Yanagawa, B., Suarez, A., Dabiri, D., Zhang, J., and McManus, B. M. (2004) J. Virol. 78, 4289-4298[Abstract/Free Full Text]
  35. Yeung, L. H., Read, J. T., Sorenson, P., Nelson, C. C., Gleave, M., Jia, W., and Rennie, P. S. (2003) Biochem. J. 371, 843-855[CrossRef][Medline] [Order article via Infotrieve]
  36. Hecht, A., and Stemmler, M. P. (2003) J. Biol. Chem. 278, 3776-3785[Abstract/Free Full Text]
  37. Korinek, V., Barker, N., Morin, P. J., van Wichen, D., de Weger, R., Kinzler, K. W., Vogelstein, B., and Clevers, H. (1997) Science 275, 1784-1787[Abstract/Free Full Text]
  38. Pap, M., and Cooper, G. M. (1998) J. Biol. Chem. 273, 19929-19932[Abstract/Free Full Text]
  39. Dignam, J. D., Lebovitz, R. M., and Roeder, R. G. (1983) Nucleic Acids Res. 11, 1475-1489[Abstract/Free Full Text]
  40. Maehama, T., and Dixon, J. E. (1999) Trends Cell Biol. 9, 125-128[CrossRef][Medline] [Order article via Infotrieve]
  41. Griendling, K. K., Sorescu, D., Lassegue, B., and Ushio-Fukai, M. (2000) Arterioscler. Thromb. Vasc. Biol. 20, 2175-2183[Abstract/Free Full Text]
  42. Quandt, K., Frech, K., Karas, H., Wingender, E., and Werner, T. (1995) Nucleic Acids Res. 23, 4878-4884[Abstract/Free Full Text]
  43. Mann, B., Gelos, M., Siedow, A., Hanski, M. L., Gratchev, A., Ilyas, M., Bodmer, W. F., Moyer, M. P., Riecken, E. O., Buhr, H. J., and Hanski, C. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 1603-1608[Abstract/Free Full Text]
  44. Conacci-Sorrell, M. E., Ben-Yedidia, T., Shtutman, M., Feinstein, E., Einat, P., and Ben-Ze'ev, A. (2002) Genes Dev. 16, 2058-2072[Abstract/Free Full Text]
  45. Lin, H., Ignatescu, M., Wilson, J. E., Roberts, C. R., Horley, K. J., Winters, G. L., Costanzo, M. R., and McManus, B. M. (1996) J. Heart Lung Transplant. 15, 1223-1232[Medline] [Order article via Infotrieve]
  46. Garratt, K. N., Edwards, W. D., Kaufmann, U. P., Vlietstra, R. E., and Holmes, D. R., Jr. (1991) J. Am. Coll. Cardiol. 17, 442-448[Abstract]
  47. Schwartz, R. S., Holmes, D. R., Jr., and Topol, E. J. (1992) J. Am. Coll. Cardiol. 20, 1284-1293[Abstract]
  48. Pollman, M. J., Hall, J. L., Mann, M. J., Zhang, L., and Gibbons, G. H. (1998) Nat. Med. 4, 222-227[CrossRef][Medline] [Order article via Infotrieve]
  49. Gibbons, G. H., and Dzau, V. J. (1996) Science 272, 689-693[Abstract]
  50. Ross, R. (1999) N. Engl. J. Med. 340, 115-126[Free Full Text]
  51. Dierick, H., and Bejsovec, A. (1999) Curr. Top. Dev. Biol. 43, 153-190[Medline] [Order article via Infotrieve]
  52. Seidensticker, M. J., and Behrens, J. (2000) Biochim. Biophys. Acta 1495, 168-182[Medline] [Order article via Infotrieve]
  53. Miller, J. R., Hocking, A. M., Brown, J. D., and Moon, R. T. (1999) Oncogene 18, 7860-7872[CrossRef][Medline] [Order article via Infotrieve]
  54. Wang, X., Xiao, Y., Mou, Y., Zhao, Y., Blankesteijn, W. M., and Hall, J. L. (2002) Circ. Res. 90, 340-347[Abstract/Free Full Text]
  55. Wang, X., Adhikari, N., Li, Q., and Hall, J. L. (2004) Am. J. Physiol. Heart Circ. Physiol. 287, H2376-H2383[Abstract/Free Full Text]
  56. Mao, C., Malek, O. T., Pueyo, M. E., Steg, P. G., and Soubrier, F. (2000) Arterioscler. Thromb. Vasc. Biol. 20, 43-51[Abstract/Free Full Text]
  57. Blankesteijn, W. M., van Gijn, M. E., Essers-Janssen, Y. P., Daemen, M. J., and Smits, J. F. (2000) Am. J. Pathol. 157, 877-883[Abstract/Free Full Text]
  58. Kishimoto, J., Burgeson, R. E., and Morgan, B. A. (2000) Genes Dev. 14, 1181-1185[Abstract/Free Full Text]
  59. Takahashi, M., Tsunoda, T., Seiki, M., Nakamura, Y., and Furukawa, Y. (2002) Oncogene 21, 5861-5867[CrossRef][Medline] [Order article via Infotrieve]
  60. Brabletz, T., Jung, A., Dag, S., Hlubek, F., and Kirchner, T. (1999) Am. J. Pathol. 155, 1033-1038[Abstract/Free Full Text]
  61. Willert, J., Epping, M., Pollack, J. R., Brown, P. O., and Nusse, R. (2002) BMC Dev. Biol. 2, 8[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
C. Domenzain-Reyna, D. Hernandez, L. Miquel-Serra, M. J. Docampo, C. Badenas, A. Fabra, and A. Bassols
Structure and Regulation of the Versican Promoter: THE VERSICAN PROMOTER IS REGULATED BY AP-1 AND TCF TRANSCRIPTION FACTORS IN INVASIVE HUMAN MELANOMA CELLS
J. Biol. Chem., May 1, 2009; 284(18): 12306 - 12317.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. K. Bentley, H. Deng, M. J. Linn, J. Lei, G. A. Dokshin, D. C. Fingar, K. N. Bitar, W. R. Henderson Jr., and M. B. Hershenson
Airway smooth muscle hyperplasia and hypertrophy correlate with glycogen synthase kinase-3{beta} phosphorylation in a mouse model of asthma
Am J Physiol Lung Cell Mol Physiol, February 1, 2009; 296(2): L176 - L184.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. T. Read, M. Rahmani, S. Boroomand, S. Allahverdian, B. M. McManus, and P. S. Rennie
Androgen Receptor Regulation of the Versican Gene through an Androgen Response Element in the Proximal Promoter
J. Biol. Chem., November 2, 2007; 282(44): 31954 - 31963.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/13/13019    most recent
M411766200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rahmani, M.
Right arrow Articles by McManus, B. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rahmani, M.
Right arrow Articles by McManus, B. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement